Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

Bibliography

• Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 Suppl 2):S1-45
   PubMed Web of Science ®Google Scholar
• Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? Med Sci Monit 2009;15(12):MS1-5
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366(9493):1267-78
   PubMed Web of Science ®Google Scholar
• Banach M, Mikhailidis DP. Statin therapy and new-onset diabetes: An attempt at recommendations. Exp Rev Endocrinol Metabol 2013;8(3):213-16
   PubMedGoogle Scholar
• Kavousi M, Leening MJ, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA 2014;311(14):1416-23
   PubMed Web of Science ®Google Scholar
• Colantonio LD, Baber U, Banach M, et al. Contrasting cholesterol management guidelines for adults with CKD. J Am Soc Nephrol 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90
   PubMed Web of Science ®Google Scholar
• Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, et al. Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol 2015;178:111-16
   PubMed Web of Science ®Google Scholar
• Banach M, Serban C, Sahebkar A, et al. Lipid and Blood Pressure Meta-analysis Collaboration Group. Effects of Coenzyme Q10 on Statin-Induced Myopathy: A Meta-analysis of Randomized Controlled Trials. Mayo Clin Proc 2015;90(1):24-34
   PubMed Web of Science ®Google Scholar
• Stroes ES, Thompson PD, Corsini A, et al. European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015. [ Epub ahead of print]
   Google Scholar
• Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med 2009;150(12):858-68
   PubMed Web of Science ®Google Scholar
• Grundy SM. Can statins cause chronic low-grade myopathy? Ann Intern Med 2002;137(7):617-18
   PubMed Web of Science ®Google Scholar
• Bays H. Statin safety: an overview and assessment of the data-2005. Am J Cardiol 2006;97:6C-26C
   PubMed Web of Science ®Google Scholar
• Bitzur R, Cohen H, Kamari Y, Harats D. Intolerance to Statins: Mechanisms and Management. Diabetes Care 2013;36:S325-30
   PubMed Web of Science ®Google Scholar
• Marciante KD, Durda JP, Heckbert SR, et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics 2011;21(5):280-8
   PubMed Web of Science ®Google Scholar
• McClure DL, Valuck RJ, Glanz M, Hokanson JE. Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present. Pharmacoepidemiol Drug Saf 2007;16(2):132-43
   PubMed Web of Science ®Google Scholar
• Banach M, Serban C, Aronow WS, et al. Lipid, blood pressure and kidney update 2013. Int Urol Nephrol 2014;46(5):947-61
   PubMed Web of Science ®Google Scholar
• Mancini GB, Tashakkor AY, Baker S, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol 2013;29:1553-68
   PubMed Web of Science ®Google Scholar
• Jacobson TA. Toward “pain-free” statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 2008;83(6):687-700
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Baker SK, Jacobson TA, et al. An assessment by the statin muscle safety task force: 2014. J Clin Lipidol 2014;8:S58-71
   PubMed Web of Science ®Google Scholar
• Reiner Z. Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis 2014;24(10):1057-66
   PubMed Web of Science ®Google Scholar
• Stephen K. Galson Acting Director U.S. Food and Drug Administration Center for Drug Evaluation and Research. FDA Rejection of Citizen Petition. Letter dated 11 March 2005, Food and Drug Administration Docket No. 2004P-0113/CP1
   Google Scholar
• Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. Cardiovasc Drugs Ther 2005;19(6):403-14
   PubMed Web of Science ®Google Scholar
• Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation 2013;127:96-103
   PubMed Web of Science ®Google Scholar
• Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group1. Armitage J, Bowman L, Wallendszus K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010;376(9753):1658-69
   PubMed Web of Science ®Google Scholar
• HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34(17):1279-91
   PubMed Web of Science ®Google Scholar
• Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818
   PubMed Web of Science ®Google Scholar
• Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol 2012;56:374-80
   PubMed Web of Science ®Google Scholar
• Bergmann OM, Kristjansson G, Jonasson JG, Björnsson ES. Jaundice due to suspected statin hepatotoxicity: a case series. Dig Dis Sci 2012;57:1959-64
   PubMed Web of Science ®Google Scholar
• Marcum ZA, Vande Griend JP, Linnebur SA. FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother 2012;10:264-71
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs (2-28-2012). Available from: http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm
   Google Scholar
• Katsiki N, Banach M. Statin use and risk of diabetes mellitus in postmenopausal women. Clin Lipidol 2012;7:267-70
   Web of Science ®Google Scholar
• Barylski M, Małyszko J, Rysz J, et al. Lipids, blood pressure, kidney - what was new in 2011? Arch Med Sci 2011;7(6):1055-66
   Web of Science ®Google Scholar
• Banach M, Malodobra-Mazur M, Gluba A, et al. Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance. Curr Pharm Des 2013;19(27):4904-12
   PubMed Web of Science ®Google Scholar
• Barylski M, Nikolic D, Banach M, et al. Statins and new-onset diabetes. Curr Pharm Des 2014;20(22):3657-64
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet 2010;375:735-42
   PubMed Web of Science ®Google Scholar
• Rajpathak SN, Kumbhani DJ, Crandall J, et al. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009;32:1924-9
   PubMed Web of Science ®Google Scholar
• Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011;305:2556-64
   PubMed Web of Science ®Google Scholar
• Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012;380:565-71
   PubMed Web of Science ®Google Scholar
• Sugiyama T, Tsugawa Y, Tseng CH, et al. Different time trends of caloric and fat intake between statin users and nonusers among US adults: gluttony in the time of statins? JAMA Intern Med 2014;174(7):1038-45
   PubMed Web of Science ®Google Scholar
• Golomb BA, Evans MA. Statin Adverse Effects: A Review of the Literature and Evidence for a Mitochondrial Mechanism. Am J Cardiovasc Drugs 2008;8:373-418
   PubMed Web of Science ®Google Scholar
• Lim S, Despres J-P, Koh KK. Prevention of Atherosclerosis in Overweight/Obese Patients-In need of novel multi-targeted approaches. Circ J 2011;75(5):1019-27
   PubMed Web of Science ®Google Scholar
• Monda KL, Ballantyne CM, North KE. Longitudinal impact of physical activity on lipid profiles in middle-aged adults: the Atherosclerosis Risk in Communities Study. J Lipid Res 2009;50(8):1685-91
   PubMed Web of Science ®Google Scholar
• Kearns AK, Bilbie CL, Clarkson PM, et al. The creatine kinase response to eccentric exercise with atorvastatin 10mg or 80mg. Atherosclerosis 2008;200(1):121-5
   PubMed Web of Science ®Google Scholar
• Meador BM, Huey KA. Statin‐associated myopathy and its exacerbation with exercise. Muscle Nerve 2010;42(4):469-79
   PubMed Web of Science ®Google Scholar
• Sinzinger H, O’Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol 2004;57(4):525-8
   PubMed Web of Science ®Google Scholar
• Parker BA, Augeri AL, Capizzi JA, et al. Effect of statins on creatine kinase levels before and after a marathon run. Am J Cardiol 2012;109(2):282-7
   PubMed Web of Science ®Google Scholar
• Thompson PD, Zmuda JM, Domalik LJ, et al. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 1997;46(10):1206-10
   PubMed Web of Science ®Google Scholar
• Kokkinos PF, Faselis C, Myers J, et al. Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study. Lancet 2013;381(9864):394-9
   PubMed Web of Science ®Google Scholar
• Westwood FR, Bigley A, Randall K, et al. Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol Pathol 2005;33(2):246-57
   PubMed Web of Science ®Google Scholar
• Kwak H-B, Thalacker-Mercer A, Anderson EJ, et al. Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes. Free Radic Biol Med 2012;52(1):198-207
   PubMed Web of Science ®Google Scholar
• Sirvent P, Fabre O, Bordenave S, et al. Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. Toxicol Appl Pharmacol 2012;259(2):263-8
   PubMed Web of Science ®Google Scholar
• Urso ML, Clarkson PM, Hittel D, et al. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol 2005;25(12):2560-6
   PubMed Web of Science ®Google Scholar
• Huh JY, Mougios V, Kabasakalis A, et al. Exercise-induced irisin secretion is independent of age or fitness level and increased irisin may directly modulate muscle metabolism through AMPK activation. J Clin Endocrinol Metabol 2014;99(11):E2154-E61
   PubMed Web of Science ®Google Scholar
• Thompson PD, Parker B. Statins, Exercise, and Exercise Training. J Am Coll Cardiol 2013;62(8):715-16
   PubMed Web of Science ®Google Scholar
• Tziomalos K, Athyros VG, Mikhailidis DP. Statin discontinuation: an underestimated risk? Curr Med Res Opin 2008;24(11):3059-62
   PubMed Web of Science ®Google Scholar
• Sirvent P, Mercier J, Lacampagne A. New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol 2008;8:333-8
   PubMed Web of Science ®Google Scholar
• Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585-90
   PubMed Web of Science ®Google Scholar
• Sirvent P, Fabre O, Bordenave S, et al. Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. Toxicol Appl Pharmacol 2012;259:263-8
   PubMed Web of Science ®Google Scholar
• Gaitonde DY, Rowley KD, Sweeney LB. Hypothyroidism: an update. Am Fam Physician 2012;86:244-51
   PubMed Web of Science ®Google Scholar
• Arruda AP, Ketzer LA, Nigro M, et al. Cold tolerance in hypothyroid rabbits: role of skeletal muscle mitochondria and sarcoplasmic reticulum Ca2+ ATPase isoform 1 heat production. Endocrinology 2008;149:6262-71
   PubMed Web of Science ®Google Scholar
• Farias Moeller R, Zecavati N, Sherafat-Kazemzadeh R, et al. Adolescent with rhabdomyolysis due to undiagnosed hypothyroidism. Case Rep Pediatr 2011;2011:670673
   Google Scholar
• Lando HM, Burman KD. Two cases of statin-induced myopathy caused by induced hypothyroidism. Endocr Pract 2008;14:726-31
   PubMedGoogle Scholar
• Kiernan TJ, Rochford M, McDermott JH. Simvastatin induced rhabdomyolysis and an important clinical link with hypothyroidism. Int J Cardiol 2007;119:374-6
   PubMed Web of Science ®Google Scholar
• Antons KA, Williams CD, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006;119:400-9
   PubMed Web of Science ®Google Scholar
• Bar SL, Holmes DT, Frohlich J. Asymptomatic hypothyroidism and statin-induced myopathy. Can Fam Physician 2007;53:428-31
   PubMed Web of Science ®Google Scholar
• Al-Salameh A, Bihan H, Keller-Petrot I, et al. Statins should be used with greater caution in patients undergoing thyroid hormone withdrawal for radioactive iodine treatment. Thyroid 2011;21:457-8
   PubMed Web of Science ®Google Scholar
• Garber JR, Cobin RH, Gharib H, et al. for the American Association of Clinical Endocrinologists and the American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical Practice Guidelines for Hypothyroidism in Adults. Thyroid 2012;22:1200-35
   PubMed Web of Science ®Google Scholar
• Rando LP, Cording SA, Newnham HH. Successful reintroduction of statin therapy after myositis: was there another cause? Med J Aust 2004;180:472-3
   PubMed Web of Science ®Google Scholar
• Lioudaki E, Mavroeidi NG, Mikhailidis DP, Ganotakis ES. Subclinical hypothyroidism and vascular risk: αn update. Hormones (Athens) 2013;12:495-506
   PubMedGoogle Scholar
• Duman D, Sahin S, Esertas K, Demirtunc R. Simvastatin improves endothelial function in patents with subclinical hypothyroidism. Heart Vessels 2007;22:88-93
   PubMed Web of Science ®Google Scholar
• Requena Carrión E, Ayala Jiménez L, Sierra García F. Renal failure due to simvastatin-induced rhabdomyolysis in a patient with subclinical hypothyroidism. Farm Hosp 2010;34(1):45-6
   PubMedGoogle Scholar
• Bryson CL, Au DH, Sun H, et al. Alcohol screening scores and medication nonadherence. Ann Intern Med 2008;149(11):795-804
   PubMed Web of Science ®Google Scholar
• Smit JW, Wijnne HJ, Schobben F, et al. Effects of alcohol and fluvastatin on lipid metabolism and hepatic function. Ann Int Med 1995;122:678-80
   PubMed Web of Science ®Google Scholar
• Mukamal KJ, Smith CC, Karlamangla AS, Moore AA. Moderate alcohol consumption and safety of lovastatin and warfarin among men: the post-coronary artery bypass graft trial. Am J Med 2006;119(5):434-40
   PubMed Web of Science ®Google Scholar
• Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5’-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem 1991;110:559-65
   PubMed Web of Science ®Google Scholar
• Fifth Joint Task Force of the European Society of Cardiology; European Association of Echocardiography; European Association of Percutaneous Cardiovascular Interventions; European Heart Rhythm Association; Heart Failure Association; European Association for Cardiovascular Prevention & Rehabilitation; European Atherosclerosis Society; International Society of Behavioural Medicine; European Stroke Organisation; European Society of Hypertension; European Association for the Study of Diabetes; European Society of General Practice/Family Medicine; International Diabetes Federation Europe; European Heart Network. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur J Prev Cardiol 2012;19(4):585-667
   Google Scholar
• Cohen DE, Anania FA, Chalasani N; National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol 2006;97:77C-81C
   PubMed Web of Science ®Google Scholar
• Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol 2006;97:S69-76
   PubMed Web of Science ®Google Scholar
• Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-92
   PubMed Web of Science ®Google Scholar
• Athyros VG, Katsiki N, Tziomalos K, GREACE Study Collaborative Group. Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. Arch Med Sci 2013;9(3):418-26
   PubMed Web of Science ®Google Scholar
• Bader T. Liver tests are irrelevant when prescribing statins. Lancet 2010;376:1882-3
   PubMed Web of Science ®Google Scholar
• Russo MW, Jacobson IM. How to use statins in patients with chronic liver disease. Cleve Clin J Med 2004;71:58-62
   PubMed Web of Science ®Google Scholar
• Tolman KG. The liver and lovastatin. Am J Cardiol 2002;89:1374-80
   PubMed Web of Science ®Google Scholar
• Lai SW, Liao KF, Lai HC, et al. Statin use and risk of hepatocellular carcinoma. Eur J Epidemiol 2013;28:485-92
   PubMed Web of Science ®Google Scholar
• Hepatitis C. WHO Fact sheet N° 164. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/
   Google Scholar
• Wang C, Gale MJr, Keller BC, et al. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol Cell 2005;18:425-34
   PubMed Web of Science ®Google Scholar
• Ali N, Allam H, Bader T, et al. Fluvastatin interferes with hepatitis C virus replication via microtubule bundling and a doublecortin-like kinase-mediated mechanism. PLoS One 2013;8:e80304
   PubMedGoogle Scholar
• Ikeda M, Kato N. Life style-related diseases of the digestive system: cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: suppression of HCV replication by statins and synergistic action with interferon. J Pharmacol Sci 2007;105:145-50
   PubMed Web of Science ®Google Scholar
• Delang L, Paeshuyse J, Vliegen I, et al. Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology 2009;50:6-16
   PubMed Web of Science ®Google Scholar
• Singh S, Singh PP, Singh AG, et al. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 2013;144:323-32
   PubMed Web of Science ®Google Scholar
• Pradelli D, Soranna D, Scotti L, et al. Statins and primary liver cancer: a meta-analysis of observational studies. Eur J Cancer Prev 2013;22:229-34
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010;376:1670-81
   PubMed Web of Science ®Google Scholar
• Stepien M, Banach M, Mikhailidis DP, et al. Role and significance of statins in the treatment of hypertensive patients. Curr Med Res Opin 2009;25(8):1995-2005
   PubMed Web of Science ®Google Scholar
• Bader T. Yes! Statins can be given to liver patients. J Hepatol 2012;56:305-7
   PubMed Web of Science ®Google Scholar
• Bradley SM, Soine LA, Caldwell JH, Goldberg SL. Screening stress myocardial perfusion imaging and eligibility for liver transplantation. Am J Cardiol 2010;105:1010-13
   PubMed Web of Science ®Google Scholar
• Balmer ML, Dufour JF. Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated. Swiss Med Wkly 2008;138:415-19
   PubMed Web of Science ®Google Scholar
• Stojakovic T, Claudel T, Putz-Bankuti C, et al. Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. Atherosclerosis 2010;209:178-83
   PubMed Web of Science ®Google Scholar
• Cash WJ, O’Neill S, O’Donnell ME, et al. Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis. Liver Int 2013;33:1166-74
   PubMed Web of Science ®Google Scholar
• Abu Rajab M, Kaplan MM. Statins in primary biliary cirrhosis: are they safe? Dig Dis Sci 2010;55:2086-8
   PubMed Web of Science ®Google Scholar
• Adiels M, Taskinen MR, Boren J. Fatty liver, insulin resistance, and dyslipidemia. Curr Diab Rep 2008;8:60-4
   PubMed Web of Science ®Google Scholar
• Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Are statins ’IDEAL’ for non-alcoholic fatty liver disease? Curr Med Res Opin 2014;30(2):229-31
   PubMed Web of Science ®Google Scholar
• Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010;52:79-104
   PubMed Web of Science ®Google Scholar
• Athyros VG, Tziomalos K, Gossios TD, et al. GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376:1916-22
   PubMed Web of Science ®Google Scholar
• Athyros VG, Giouleme O, Ganotakis ES, et al. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci 2011;7:796-805
   PubMed Web of Science ®Google Scholar
• Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Smoking and non-alcoholic steatohepatitis (NASH): the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial. J Hepatol 2012;57:476
   PubMedGoogle Scholar
• Athyros VG, Tziomalos K, Daskalopoulos GN, et al. Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone? Ann Med 2011;43:167-71
   PubMed Web of Science ®Google Scholar
• Foster T, Budoff MJ, Saab S, et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 2011;106:71-7
   PubMed Web of Science ®Google Scholar
• Tikkanen MJ, Fayyad R, Faergeman O, et al. On behalf of the IDEAL Investigators. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 2013;168:3846-52
   PubMed Web of Science ®Google Scholar
• Nikolic D, Banach M, Nikfar S, Lipid and Blood Pressure Meta-Analysis Collaboration Group. A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important? Int J Cardiol 2013;168(6):5437-47
   PubMed Web of Science ®Google Scholar
• Lonardo A, Sookoian S, Chonchol M, et al. Cardiovascular and systemic risk in nonalcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD. Curr Pharm Des 2013;19:5177-92
   PubMed Web of Science ®Google Scholar
• Abrass CK. Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol 2003;24(1):46-53
   PubMed Web of Science ®Google Scholar
• Gluba A, Rysz J, Banach M. Statins in patients with chronic kidney disease: why, who and when? Expert Opin Pharmacother 2010;11(16):2665-74
   PubMed Web of Science ®Google Scholar
• Rysz J, Aronow WS, Stolarek RS, et al. Nephroprotective and clinical potential of statins in dialyzed patients. Expert Opin Ther Targets 2009;13(5):541-50
   PubMed Web of Science ®Google Scholar
• Shepherd J, Kastelein JJ, Bittner V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008;51(15):1448-54
   PubMed Web of Science ®Google Scholar
• Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004;15(5):1307-15
   PubMed Web of Science ®Google Scholar
• Barylski M, Nikfar S, Mikhailidis DP, Lipid and Blood Pressure Meta-Analysis Collaboration Group. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy–a meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res 2013;72:35-44
   PubMed Web of Science ®Google Scholar
• Dormuth CR, Hemmelgarn BR, Paterson JM, et al. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. Bmj 2013;346:f880
   PubMed Web of Science ®Google Scholar
• Marenzi G, Cosentino N, Werba JP, et al. A meta-analysis of randomized controlled trials on statins for the prevention of contrast-induced acute kidney injury in patients with and without acute coronary syndromes. Int J Cardiol 2015;183:47-53
   PubMed Web of Science ®Google Scholar
• Gluba A, Banach M, Hannam S, et al. The role of Toll-like receptors in renal diseases. Nat Rev Nephrol 2010;6(4):224-35
   PubMed Web of Science ®Google Scholar
• Rysz J, Banach M, Cialkowska-Rysz A, et al. Blood serum levels of IL-2, IL-6, IL-8, TNF-alpha and IL-1beta in patients on maintenance hemodialysis. Cell Mol Immunol 2006;3(2):151-4
   PubMed Web of Science ®Google Scholar
• Tonelli M, Wanner C; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2013 clinical practice guideline. Ann Int Med 2014;160(3):182-9
   PubMed Web of Science ®Google Scholar
• Frishman WH, Aronow WS, Cheng-Lai A. Cardiovascular drug therapy in the elderly. In: Aronow WS, Fleg J, Rich MW, editors. Tresch and Aronow’s cardiovascular disease in the elderly. 5th edition. CRC Press; Boca Raton, London, New York: 2013. p. 67-103
   Google Scholar
• Szadkowska I, Stanczyk A, Aronow WS, et al. Arch Gerontol Geriatr 2010;50:114-18
   PubMed Web of Science ®Google Scholar
• Novak LP. Aging, total body potassium, fat-free mass and cell mass in males and females between the ages of 18 and 85 years. J Gerontol 1972;27:438-43
   PubMedGoogle Scholar
• Schmucker DL. Aging and drug disposition: an update. Pharmacol Rev 1985;37:133-48
   PubMed Web of Science ®Google Scholar
• Cheng JWM, Frishman WH, Aronow WS. Updates on cytochrome P450-mediated cardiovascular drug interactions. Am J Ther 2009;16:155-63
   PubMed Web of Science ®Google Scholar
• Armitage J. The safety of statins in clinical practice. Lancet 2007;370:1781-90
   PubMed Web of Science ®Google Scholar
• Thomas JE, Foody JM. Disorders of lipid metabolism. In: Aronow WS, Fleg JL, Rich MW, editors. Cardiovascular disease in the elderly. 4th edition. Informa Healthcare; New York, London: 2008. p. 159-78
   Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Eng J Med 2005;352:1425-35
   PubMed Web of Science ®Google Scholar
• Roberts CGP, Guallar E, Rodriguez A. Efficacy and safety of statin monotherapy in older adults: a meta-analysis. J Gerontol Med Sci 2007;62A:879-87
   Google Scholar
• Martin SS, Blumenthal RS. Disorders of lipid metabolism. In: Aronow WS, Fleg J, Rich MW, editors. Tresch and Aronow’s cardiovascular disease in the elderly. 5th edition. CRC press; Boca Raton, London, New York: 2013. p. 121-42
   Google Scholar
• Sica DA, Gehr TW. Rhabdomyolysis and statin therapy: relevance to the elderly. Am J Geriatr Cardiol 2002;11:48-55
   PubMedGoogle Scholar
• Rizzo M, Nikolic D, Banach M, Montalto G. Statin treatment in the elderly: how much do we know? Arch Med Sci 2013;9(4):585-8
   Web of Science ®Google Scholar
• McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004;363(9426):2015-21
   PubMed Web of Science ®Google Scholar
• Mihos CG, Artola RT, Santana O. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive review. Rheumatol Int 2012;32(2):287-94
   PubMed Web of Science ®Google Scholar
• Buettner C, Rippberger MJ, Smith JK, et al. Statin use and musculoskeletal pain among adults with and without arthritis. Am J Med 2012;125:176-82
   PubMed Web of Science ®Google Scholar
• de Jong HJ, Saldi SR, Klungel OH, et al. Statin-associated polymyalgia rheumatica. An analysis using WHO global individual case safety database: a case/non-case approach. PLoS One 2012;7:e41289
   PubMedGoogle Scholar
• de Jong HJ, Klungel OH, van Dijk L, et al. Use of statins is associated with an increased risk of rheumatoid arthritis. Ann Rheum Dis 2012;71(5):648-54
   PubMed Web of Science ®Google Scholar
• Moulis G, Bene J, Sommet A, et al. French Association of PharmacoVigilance Centres. Statin-induced lupus: a case/noncase study in a nationwide pharmacovigilance database. Lupus 2012;21:885-9
   PubMed Web of Science ®Google Scholar
• Noel B. Lupus erythematosus and other autoimmune diseases related to statin therapy: A systematic review. J Eur Acad Dermatol Venereol 2007;21:17-24
   PubMed Web of Science ®Google Scholar
• del Rincón ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in rheumatoid arthritis cohort not explained by traditional risk factors. Arthritis Rheum 2001;44:2737-45
   PubMed Web of Science ®Google Scholar
• De Vera MA, Choi H, Abrahamowicz M, et al. Impact of statin discontinuation on mortality in patients with rheumatoid arthritis: a population-based study. Arthritis Care Res (Hoboken) 2012;64:809-16
   PubMed Web of Science ®Google Scholar
• Liakopoulos OJ, Choi YH, Haldenwang PL, et al. Impact of preoperative statin therapy on adverse postoperative out-comes in patients undergoing cardiac surgery: a meta-analysis of over 30,000 patients. Eur Heart J 2008;29:1548-59
   PubMed Web of Science ®Google Scholar
• Molnar AO, Coca SG, Devereaux PJ, et al. Statin use associates with a lower incidence of acute kidney injury after major elective surgery. J Am Soc Nephrol 2011;22(5):939-46
   PubMed Web of Science ®Google Scholar
• Iannuzzi JC, Rickles AS, Kelly KN, et al. Perioperative pleiotropic statin effects in general surgery. Surgery 2014;155(3):398-407
   PubMed Web of Science ®Google Scholar
• Lindenauer PK, Pekow P, Wang K, et al. Lipid lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 2004;291(17):2092-9
   PubMed Web of Science ®Google Scholar
• Hindler K, Shaw AD, Samuels J, et al. Improved postoperative outcomes associated with preoperative statin therapy. Anesthesiology 2006;105(6):1260-72
   PubMed Web of Science ®Google Scholar
• Poldermans D, Bax JJ, Boersma E, et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J 2009;30(22):2769-812
   PubMed Web of Science ®Google Scholar
• Le Manach Y, Godet G, Coriat P, et al. The impact of post-operative discontinuation or continuation of chronic statin therapy on cardiac outcome after major vascular surgery. Anesth Analg 2007;104:1326-33
   PubMed Web of Science ®Google Scholar
• Kristensen SD, Knuuti J, Saraste A, et al. Authors/Task Force Members. 2014 ESC/EAS Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2014;35(35):2383-431
   PubMed Web of Science ®Google Scholar
• Degreef LE, Opdam FL, Teepe-Twiss IM, et al. The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients. Eur J Intern Med 2010;21:293-6
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Abuchaibe C, Wang P. Symptomatic myositis-myalgia in hypercholesterolemic statin-treated patients with concurrent vitamin D deficiency leading to statin intolerance may reflect a reversible interaction between vitamin D deficiency and statins on skeletal muscle. Med Hypotheses 2011;77:658-61
   PubMed Web of Science ®Google Scholar
• Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012;308:2497-506
   PubMed Web of Science ®Google Scholar
• Banach M, Aronow WS, Serban C, et al. Lipids, blood pressure and kidney update 2014. Pharmacol Res 2015; In press
   Web of Science ®Google Scholar
• Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014;63(23):2541-8
   PubMed Web of Science ®Google Scholar
• Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3 (GAUSS-3). ClinicalTrials.gov Identifier: NCT01984424
   Google Scholar
• Dragan S, Serban MC, Banach M. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy? J Cardiovasc Pharmacol Ther 2015;20(2):157-68
   PubMed Web of Science ®Google Scholar
• Moriarty PM, Jacobson TA, Bruckert E, et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol 2014;8(6):554-61
   PubMed Web of Science ®Google Scholar
• Guyton JR, Bays HE, Grundy SM, Jacobson TA; The National Lipid Association Statin Intolerance Panel. An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol 2014;8(3 Suppl):S72-81
   PubMed Web of Science ®Google Scholar
• Visser ME, Wagener G, Baker BF, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J 2012;33:1142-9
   PubMed Web of Science ®Google Scholar
• Donnelly LA, Doney AS, Tavendale R, et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin Pharmacol Ther 2011;89:210-16
   PubMed Web of Science ®Google Scholar
• Raju SB, Varghese K, Madhu K. Management of statin intolerance. Indian J Endocrinol Metab 2013;17:977-82
   PubMedGoogle Scholar
• Finegold JA, Manisty CH, Goldacre B, et al. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prevent Cardiol 2014;21(4):464-74
   PubMed Web of Science ®Google Scholar
• Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf 2011;10:373-87
   PubMed Web of Science ®Google Scholar
• Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97:52C-60C
   PubMed Web of Science ®Google Scholar
• Needham M, Mastaglia FL. Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul Disord 2014;24:4-15
   PubMed Web of Science ®Google Scholar
• Bays H, Cohen DE, Chalasani N, Harrison SA; The National Lipid Association’s Statin Safety Task Force. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol 2014;8(3 Suppl):S47-57
   PubMed Web of Science ®Google Scholar
• Wei MY, Ito MK, Cohen JD, et al. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol 2013;7(5):472-83
   PubMed Web of Science ®Google Scholar
• Sathasivam S, Lecky B. Statin induced myopathy. BMJ 2008;337:a2286
   PubMedGoogle Scholar
• Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581-5
   PubMed Web of Science ®Google Scholar
• Abukres SH, Hoti K, Hughes JD. Patient attitudes towards a new role for pharmacists: continued dispensing. Patient Prefer Adherence 2014;8:1143-51
   PubMed Web of Science ®Google Scholar
• Fernández AB, Karas RH, Alsheikh-Ali AA, Thompson PD. Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports. CHEST J 2008;134(4):824-30
   PubMed Web of Science ®Google Scholar
• Vandiver W, Hunter ML. Statin adverse effects: Sorting out the evidence. Fam Pract 2013;62:730
   Google Scholar
• Zureik M, Courbon D, Ducimetiere P. Serum cholesterol concentration and death from suicide in men: Paris prospective study I. BMJ 1996;313(7058):649-51
   PubMed Web of Science ®Google Scholar
• Olson MB, Kelsey SF, Matthews KA, et al. Lipid-lowering medication use and aggression scores in women: a report from the NHLBI-sponsored WISE study. J Womens Health 2008;17(2):187-94
   Web of Science ®Google Scholar
• Kang J-H, Kao L-T, Lin H-C, et al. Statin use increases the risk of depressive disorder in stroke patients: A population-based study. J Neurol Sci 2015;348(1–2):89-93
   PubMed Web of Science ®Google Scholar
• Amarenco P, Bogousslavsky J, Callahan A; Investigators SPbARiCL. High-dose atorvastatin after stroke or transient ischemic attack. J Vasc Surg 2006;44(6):1374
   Google Scholar
• Golomb BA, Kane T, Dimsdale JE. Severe irritability associated with statin cholesterol-lowering drugs. QJM 2004;97(4):229-35
   PubMed Web of Science ®Google Scholar
• Tuccori M, Lapi F, Testi A, et al. Statin-associated psychiatric adverse events. Drug Saf 2008;31(12):1115-23
   PubMed Web of Science ®Google Scholar
• Boriani G, Biffi M, Strocchi E, Branzi A. Nightmares and sleep disturbances with simvastatin and metoprolol. Ann Pharmacother 2001;35(10):1292
   PubMed Web of Science ®Google Scholar
• Carter AA, Gomes T, Camacho X, et al. Risk of incident diabetes among patients treated with statins: population based study. Bmj 2013;346:f2610
   PubMed Web of Science ®Google Scholar
• Segal AS. Alopecia associated with atorvastatin. Am J Med 2002;113(2):171
   PubMed Web of Science ®Google Scholar
• Pua VS, Scolyer RA, Barnetson RS. Pravastatin - induced lichenoid drug eruption. Australas J Dermatol 2006;47(1):57-9
   PubMed Web of Science ®Google Scholar
• Adcock B, Hornsby L, Jenkins K. Dermographism: an adverse effect of atorvastatin. J Am Board Fam Pract 2001;14(2):148-51
   PubMedGoogle Scholar
• Anliker M, Wüthrich B. Chronic urticaria to atorvastatin. Allergy 2002;57(4):366
   PubMed Web of Science ®Google Scholar
• Pfeiffer CM, Kazenoff S, Rothberg HD. Toxic epidermal necrolysis from atorvastatin. JAMA 1998;279(20):1613-14
   PubMed Web of Science ®Google Scholar
• Krasovec M, Elsner P, Burg G. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors. Dermatology 1993;186(4):248-52
   PubMed Web of Science ®Google Scholar
• Leuschen J, Mortensen EM, Frei CR, et al. Association of statin use with cataracts: a propensity score–matched analysis. JAMA Ophthalmol 2013;131(11):1427-34
   PubMedGoogle Scholar
• Fraunfelder F, Richards AB. Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use. Ophthalmology 2008;115(12):2282-5
   PubMed Web of Science ®Google Scholar
• Athyros VG, Elisaf M, Papageorgiou AA, et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004;43(4):589-99
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010;340:c2197
   PubMed Web of Science ®Google Scholar
• Kostis JB, Dobrzynski JM. The effect of statins on erectile dysfunction: a meta – analysis of randomized trials. J Sex Med 2014;11(7):1626-35
   PubMed Web of Science ®Google Scholar
• De Graaf L, Brouwers A, Diemont W. Is decreased libido associated with the use of HMG – CoA - reductase inhibitors? Br J Clin Pharmacol 2004;58(3):326-8
   PubMed Web of Science ®Google Scholar
• Roberto G, Biagi C, Montanaro N, et al. Statin-associated gynecomastia: evidence coming from the Italian spontaneous ADR reporting database and literature. Eur J Clin Pharmacol 2012;68(6):1007-11
   PubMed Web of Science ®Google Scholar
• Schooling CM, Au Yeung SL, Freeman G, Cowling BJ. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med 2013;11:57
   PubMed Web of Science ®Google Scholar
• Groneberg DA, Barkhuizen A, Jeha T. Simvastatin – induced thrombocytopenia. Am J Hematol 2001;67(4):277
   PubMed Web of Science ®Google Scholar
• McCarthy LJ, Porcu P, Fausel CA, et al. Thrombotic thrombocytopenic purpura and simvastatin. Lancet 1998;352(9136):1284-5
   PubMed Web of Science ®Google Scholar
• McCarthy LJ, Dlott JS, Orazi A, et al. Thrombotic thrombocytopenic purpura: yesterday, today, tomorrow. Ther Apher Dial 2004;8(2):80-6
   PubMed Web of Science ®Google Scholar